Fractyl Health (GUTS) Change in Account Payables (2023 - 2026)
Fractyl Health's (GUTS) quarterly Change in Account Payables came in at $75000.0 in Q1 2026, up 104.26% YoY from $36718.1 in Q1 2025, and down 76.42% on a QoQ basis from $318000.0 in Q4 2025.
Fractyl Health (GUTS) Change in Account Payables (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Change in Account Payables data on file, last reported at $75000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 104.26% year-over-year to $75000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170000.0 (down 60.56% YoY) and the FY2025 annual result came in at -$1.7 million, down 162.03% from the prior year.
- Change in Account Payables retreated to $75000.0 in Q1 2026, from $318000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.4 million in Q2 2025 to a low of -$2.7 million in Q3 2025.
- A 4-year average of $51384.6 and a median of $75000.0 in 2026 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables surged 1854.55% — and 2025, when it slumped 652.12%.
- Tracing GUTS's Change in Account Payables over 4 years: stood at $77000.0 in 2023, then surged by 1854.55% to $1.5 million in 2024, then slumped by 78.87% to $318000.0 in 2025, then plunged by 76.42% to $75000.0 in 2026.
- The last three Change in Account Payables figures came in at $75000.0 (Q1 2026), $318000.0 (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -643,000.00 |
| Jun 30, 2026 | -643,000.00 |
| Mar 31, 2026 | 75,000.00 |
| Mar 31, 2026 | 75,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | -2.66 Mn |
| Sep 30, 2025 | -2.66 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Mar 31, 2025 | -1.76 Mn |
| Mar 31, 2025 | -1.76 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | -353,000.00 |
| Sep 30, 2024 | -353,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 494,000.00 |
| Mar 31, 2024 | 494,000.00 |